Ashland is expanding its R&D Center of Excellence in Wilmington with additional formulation development and GMP manufacturing capabilities for solid dispersions and oral solid dosages to support early-stage clinical trials. The expansion will include spray drying and extrusion processes previously located in Columbia, MD and approximately 20 positions will be relocated to Wilmington. The new facility is expected to be operational by summer 2014.
“This expansion highlights our ability to provide high-value ingredients backed with superior technical support," said May Shana’a, vice president, Technology and Growth Strategy, Ashland Specialty Ingredients. “This Center of Excellence, combined with our multiple technical support labs around the world, will enable Ashland to deepen our relationship with customers and allow us to quickly solve customer problems.”